Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after Hyperkalemia
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Renal Medicine. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Uppsala Clinical Research Center (UCR).ORCID iD: 0000-0001-7545-5585
Ludwig Maximilians Univ Munchen, LMU Klinikum, Div Nephrol, Med Klin & Poliklin 4, Munich, Germany..
Portsmouth Hosp Univ NHS Trust, Dept Cardiol, Portsmouth, England..
Hosp Univ I Politecn Fe, Cardiol Dept, Valencia, Spain..
Show others and affiliations
2024 (English)In: KIDNEY360, ISSN 2641-7650, Vol. 5, no 12, p. 1813-1823Article in journal (Refereed) Published
Abstract [en]

Key PointsRenin-angiotensin-aldosterone system inhibitor (RAASi) therapy is frequently downtitrated or discontinued after a hyperkalemia episode.Reducing RAASi therapy after a hyperkalemia episode is associated with increased risk of hospitalization compared with maintaining RAASi.Our data suggest that a hospitalization within 6 months could be avoided if 25 patients maintained instead of reduced their RAASi therapy.BackgroundRenin-angiotensin-aldosterone system inhibitor (RAASi) therapy provides cardiorenal protection but is often downtitrated or discontinued after a hyperkalemia episode. This observational study describes the extent of hyperkalemia-related RAASi reduction in patients with CKD and/or heart failure (HF) and estimates the number needed to treat (NNT) to avoid a first hospitalization if RAASi had been maintained at the prior dose.MethodsHealth care registers and claims data from Germany, Spain, Sweden, and the United Kingdom were used to identify nondialysis patients with CKD and/or HF who had a hyperkalemia episode while on RAASi. Patients whose RAASi therapy was reduced (downtitrated/discontinued) after the hyperkalemia episode were propensity score matched to those with maintained RAASi, and their risks of a hospitalization within 6 months were estimated using the Kaplan-Meier method. On the basis of the absolute difference in this 6-month risk, the NNT framework was applied to estimate the number of patients who needed to have maintained instead of reduced their RAASi to avoid a first hospitalization during this period.ResultsOverall, 40,059 patients from Germany, Spain, Sweden, and the United Kingdom were included. Presence of CKD at baseline was similar across countries (72%-92%), while HF was less common in Spain (18%) versus other countries (32%-71%). After the hyperkalemia episode, RAASi was reduced in 25%-57% of patients. After propensity score matching, the 6-month risk of hospitalization was consistently higher in those with reduced versus maintained RAASi; the absolute risk difference ranged from 2.7% to 7.3%. Applying the NNT framework, these data suggest that a first hospitalization within 6 months could potentially have been avoided if 25 patients had maintained instead of reduced their RAASi.ConclusionsOur findings suggest a potential for avoiding a first hospitalization, even within a short time frame, by increasing adherence to guidelines to maintain instead of reduce RAASi after a hyperkalemia episode.

Place, publisher, year, edition, pages
Wolters Kluwer, 2024. Vol. 5, no 12, p. 1813-1823
Keywords [en]
ACE inhibitors, CKD, clinical epidemiology, electrolytes, epidemiology and outcomes, heart failure, hospitalization, renin angiotensin system
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:uu:diva-554785DOI: 10.34067/KID.0000000000000561ISI: 001385357600019PubMedID: 39167454Scopus ID: 2-s2.0-85202156985OAI: oai:DiVA.org:uu-554785DiVA, id: diva2:1952749
Funder
AstraZenecaAvailable from: 2025-04-16 Created: 2025-04-16 Last updated: 2025-04-16Bibliographically approved

Open Access in DiVA

fulltext(672 kB)18 downloads
File information
File name FULLTEXT01.pdfFile size 672 kBChecksum SHA-512
6196f1403205790bc1a05fd23f57c5be59a39b2749550bc726966cda9f857a2179c7f05577254ebbd050cf1617378c82481debaa1a8cb0a2ade928c6f033da45
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Svensson, Maria K.Lesen, EvaFranzen, StefanAllum, AlasterKossack, Nils
By organisation
Renal MedicineUppsala Clinical Research Center (UCR)
Cardiology and Cardiovascular Disease

Search outside of DiVA

GoogleGoogle Scholar
Total: 19 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf